Refractory Solid Tumor
10
3
3
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
20.0%
2 terminated out of 10 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Oxaliplatin for Children With Solid Tumors